Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227Julie R. Brahmer, Suresh S. Ramalingam, László Urbán et al.|Journal of Clinical Oncology|2022Cited by 375
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumoursEdwina N. Scott, Johann S. de Bono, Anne Thomas et al.|Cancer Chemotherapy and Pharmacology|2009Cited by 34